These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 23867634)

  • 1. Successful everolimus treatment in a patient with advanced pancreatic neuroendocrine tumor who developed everolimus-induced interstitial lung disease on two occasions: a case report.
    Nakayama Y; Ikeda M; Kojima M; Goto K; Hara M; Okuyama H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Okusaka T
    Chemotherapy; 2013; 59(1):74-8. PubMed ID: 23867634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of everolimus in pancreatic neuroendocrine tumors.
    Goldstein R; Meyer T
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma.
    Mizuno R; Asano K; Mikami S; Nagata H; Kaneko G; Oya M
    Jpn J Clin Oncol; 2012 May; 42(5):442-6. PubMed ID: 22438405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
    Thompson LA; Kim M; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus dramatically improves glycemic control in unresectable metastatic insulinoma: a case report.
    Asayama M; Yamada-Murano T; Hara H; Ooki A; Kurosumi M; Yamaguchi K
    Jpn J Clin Oncol; 2014 Feb; 44(2):186-90. PubMed ID: 24367043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amenorrhea as a rare drug-related adverse event associated with everolimus for pancreatic neuroendocrine tumors.
    Kawaguchi Y; Maruno A; Kawashima Y; Ito H; Ogawa M; Mine T
    World J Gastroenterol; 2014 Nov; 20(42):15920-4. PubMed ID: 25400479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect of everolimus in a patient with type 3 gastric neuroendocrine tumor.
    Bariani GM; Carvalheira JB; Riechelmann RP
    Onkologie; 2013; 36(9):502-4. PubMed ID: 24051927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Everolimus for the treatment of pancreatic neuroendocrine tumors.
    Feldmann G; Bisht S; Schütte U; Haarmann J; Brossart P
    Expert Opin Pharmacother; 2012 Oct; 13(14):2073-84. PubMed ID: 22873789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological Characteristics of Everolimus-Associated Interstitial Lung Disease: A Single-Center Consecutive Analysis.
    Saito Y; Terasaki Y; Kashiwada T; Tanaka T; Takei H; Kimura G; Kondo Y; Kawagoe T; Matsushita A; Noro R; Minegishi Y; Kamio K; Seike M; Gemma A
    J Nippon Med Sch; 2024 May; 91(2):207-217. PubMed ID: 38233124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
    Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
    Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rechallenge of everolimus for metastatic renal cell carcinoma after recovery from grade 3 interstitial lung disease: a case report].
    Utsunomiya N; Kono Y; Matsumoto K; Matsumoto T; Nakagawa A; Tsunemori H; Okada T; Muguruma K; Kawakita M
    Hinyokika Kiyo; 2014 Jan; 60(1):25-8. PubMed ID: 24594769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors.
    Wolin EM
    Chemotherapy; 2014; 60(3):143-50. PubMed ID: 25766415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequencing and combining systemic therapies for pancreatic neuroendocrine tumors.
    Kulke MH
    J Clin Oncol; 2015 May; 33(14):1534-8. PubMed ID: 25870092
    [No Abstract]   [Full Text] [Related]  

  • 15. Granuloma-forming interstitial pneumonia occurring one year after the start of everolimus therapy.
    Saito Y; Kunugi S; Suzuki Y; Narita K; Miura Y; Minegishi Y; Kimura G; Kondo Y; Azuma A; Fukuda Y; Gemma A
    Intern Med; 2013; 52(2):263-7. PubMed ID: 23318860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in pancreatic neuroendocrine tumor treatment.
    van der Veldt AA; Kleijn SA
    N Engl J Med; 2011 May; 364(19):1873; author reply 1873-5. PubMed ID: 21561355
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeted agents in treatment of neuroendocrine tumors of pancreas.
    Karampelas IN; Syrigos KN; Saif MW
    JOP; 2014 Jul; 15(4):351-3. PubMed ID: 25076341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Response to Everolimus Therapy Detected on 68Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor.
    Ozkan E; Soydal C; Ucak Semirgin S; Yapici O; Atmaca A; Demirag G
    Clin Nucl Med; 2016 Jul; 41(7):561-3. PubMed ID: 27163457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors.
    Phan AT
    Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):3-5. PubMed ID: 25768101
    [No Abstract]   [Full Text] [Related]  

  • 20. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L; Schwarz RE
    Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.